Design and evaluation of an oral controlled release delivery system for melatonin in human subjects

Beom Jin Lee, Keith A. Parrott, James W. Ayres, Robert Sack

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Six human subjects were given an oral formulation designed to provide an immediate and controlled release of melatonin (MT). The controlled release formulation consisted of MT-loaded sugar beads coated with 20% Aquacoat®. A computer simulation program (MAXSIM®) was used to estimate the MT dose and ratio of immediate and controlled release MT based on average population pharmacokinetics of MT. When 0.5 mg of MT (immediate release portion of MT, 0.1 mg) was administered to four subjects, average peak plasma MT concentration was reached at about 600 pg/ml and maintained at about 100 pg/ml over 8 h. Observed peak plasma MT concentrations were 3-times greater than predicted by simulation. These results suggest that the MT dose, ratio of immediate release MT to controlled release MT, and the controlled release dosage form must all be considered in order to closely mimic the endogenous plasma MT concentration-time curve. Deconvolution and pharmacokinetic analysis suggested that less than 20% of the orally administered controlled release MT dose reached the systemic circulation from time 0 to 8 h. A good correlation was observed between plasma MT concentration and urinary excretion rate of 6-sulphatoxymelatonin (6-STMT), a major metabolite of MT. As plasma MT concentration increased, the urinary excretion rate of 6-STMT increased concomitantly. This suggests that the urinary excretion rate of 6-STMT may be used as an index of human plasma MT concentration.

Original languageEnglish (US)
Pages (from-to)119-127
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume124
Issue number1
DOIs
StatePublished - Sep 19 1995

Fingerprint

Melatonin
Pharmacokinetics
Dosage Forms

Keywords

  • 6-Sulfatoxymelatonin
  • Coated bead
  • Computer simulation
  • Controlled release
  • Deconvolution
  • Immediate release
  • Melatonin

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Design and evaluation of an oral controlled release delivery system for melatonin in human subjects. / Lee, Beom Jin; Parrott, Keith A.; Ayres, James W.; Sack, Robert.

In: International Journal of Pharmaceutics, Vol. 124, No. 1, 19.09.1995, p. 119-127.

Research output: Contribution to journalArticle

Lee, Beom Jin ; Parrott, Keith A. ; Ayres, James W. ; Sack, Robert. / Design and evaluation of an oral controlled release delivery system for melatonin in human subjects. In: International Journal of Pharmaceutics. 1995 ; Vol. 124, No. 1. pp. 119-127.
@article{3d08342faf584896a44f588e87c9aed3,
title = "Design and evaluation of an oral controlled release delivery system for melatonin in human subjects",
abstract = "Six human subjects were given an oral formulation designed to provide an immediate and controlled release of melatonin (MT). The controlled release formulation consisted of MT-loaded sugar beads coated with 20{\%} Aquacoat{\circledR}. A computer simulation program (MAXSIM{\circledR}) was used to estimate the MT dose and ratio of immediate and controlled release MT based on average population pharmacokinetics of MT. When 0.5 mg of MT (immediate release portion of MT, 0.1 mg) was administered to four subjects, average peak plasma MT concentration was reached at about 600 pg/ml and maintained at about 100 pg/ml over 8 h. Observed peak plasma MT concentrations were 3-times greater than predicted by simulation. These results suggest that the MT dose, ratio of immediate release MT to controlled release MT, and the controlled release dosage form must all be considered in order to closely mimic the endogenous plasma MT concentration-time curve. Deconvolution and pharmacokinetic analysis suggested that less than 20{\%} of the orally administered controlled release MT dose reached the systemic circulation from time 0 to 8 h. A good correlation was observed between plasma MT concentration and urinary excretion rate of 6-sulphatoxymelatonin (6-STMT), a major metabolite of MT. As plasma MT concentration increased, the urinary excretion rate of 6-STMT increased concomitantly. This suggests that the urinary excretion rate of 6-STMT may be used as an index of human plasma MT concentration.",
keywords = "6-Sulfatoxymelatonin, Coated bead, Computer simulation, Controlled release, Deconvolution, Immediate release, Melatonin",
author = "Lee, {Beom Jin} and Parrott, {Keith A.} and Ayres, {James W.} and Robert Sack",
year = "1995",
month = "9",
day = "19",
doi = "10.1016/0378-5173(95)00088-Z",
language = "English (US)",
volume = "124",
pages = "119--127",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Design and evaluation of an oral controlled release delivery system for melatonin in human subjects

AU - Lee, Beom Jin

AU - Parrott, Keith A.

AU - Ayres, James W.

AU - Sack, Robert

PY - 1995/9/19

Y1 - 1995/9/19

N2 - Six human subjects were given an oral formulation designed to provide an immediate and controlled release of melatonin (MT). The controlled release formulation consisted of MT-loaded sugar beads coated with 20% Aquacoat®. A computer simulation program (MAXSIM®) was used to estimate the MT dose and ratio of immediate and controlled release MT based on average population pharmacokinetics of MT. When 0.5 mg of MT (immediate release portion of MT, 0.1 mg) was administered to four subjects, average peak plasma MT concentration was reached at about 600 pg/ml and maintained at about 100 pg/ml over 8 h. Observed peak plasma MT concentrations were 3-times greater than predicted by simulation. These results suggest that the MT dose, ratio of immediate release MT to controlled release MT, and the controlled release dosage form must all be considered in order to closely mimic the endogenous plasma MT concentration-time curve. Deconvolution and pharmacokinetic analysis suggested that less than 20% of the orally administered controlled release MT dose reached the systemic circulation from time 0 to 8 h. A good correlation was observed between plasma MT concentration and urinary excretion rate of 6-sulphatoxymelatonin (6-STMT), a major metabolite of MT. As plasma MT concentration increased, the urinary excretion rate of 6-STMT increased concomitantly. This suggests that the urinary excretion rate of 6-STMT may be used as an index of human plasma MT concentration.

AB - Six human subjects were given an oral formulation designed to provide an immediate and controlled release of melatonin (MT). The controlled release formulation consisted of MT-loaded sugar beads coated with 20% Aquacoat®. A computer simulation program (MAXSIM®) was used to estimate the MT dose and ratio of immediate and controlled release MT based on average population pharmacokinetics of MT. When 0.5 mg of MT (immediate release portion of MT, 0.1 mg) was administered to four subjects, average peak plasma MT concentration was reached at about 600 pg/ml and maintained at about 100 pg/ml over 8 h. Observed peak plasma MT concentrations were 3-times greater than predicted by simulation. These results suggest that the MT dose, ratio of immediate release MT to controlled release MT, and the controlled release dosage form must all be considered in order to closely mimic the endogenous plasma MT concentration-time curve. Deconvolution and pharmacokinetic analysis suggested that less than 20% of the orally administered controlled release MT dose reached the systemic circulation from time 0 to 8 h. A good correlation was observed between plasma MT concentration and urinary excretion rate of 6-sulphatoxymelatonin (6-STMT), a major metabolite of MT. As plasma MT concentration increased, the urinary excretion rate of 6-STMT increased concomitantly. This suggests that the urinary excretion rate of 6-STMT may be used as an index of human plasma MT concentration.

KW - 6-Sulfatoxymelatonin

KW - Coated bead

KW - Computer simulation

KW - Controlled release

KW - Deconvolution

KW - Immediate release

KW - Melatonin

UR - http://www.scopus.com/inward/record.url?scp=0029047452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029047452&partnerID=8YFLogxK

U2 - 10.1016/0378-5173(95)00088-Z

DO - 10.1016/0378-5173(95)00088-Z

M3 - Article

AN - SCOPUS:0029047452

VL - 124

SP - 119

EP - 127

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -